Age-dependent igg subclass responses to Plasmodium falciparum EBA-175 are differentially associated with incidence of malaria in Mozambican children

Clinical and Vaccine Immunology

Volumn 19, Issue 2, 2012, Pages 157-166

  Dobaño, Carlota ^a,b   Quelhas, Diana ^b   Quintó, Llorenç ^a   Puyol, Laura ^a   Serra Casas, Elisa ^a   Mayor, Alfredo ^a,b   Nhampossa, Tacilta ^b,c   Macete, Eusebio ^b,d   Aide, Pedro ^b,c   Mandomando, Inacio ^b,c   Sanz, Sergi ^a   Puniya, Sanjeev K ^e   Singh, Bijender ^e   Gupta, Puneet ^e   Bhattacharya, Arindam ^e   Chauhan, Virander S ^e   Aponte, John J ^a,b   Chitnis, Chetan E ^e   Alonso, Pedro L ^a,b   Menéndez, Clara ^a,b  

^a CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^b Ministérioda Saúde   (Mozambique)

^c INSTITUTO NACIONAL DE SAÚDE   (Mozambique)

^d International Centre for Genetic Engineering and Biotechnology ^*  (Mozambique)

^e INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY ICGEB   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; APICAL MEMBRANE ANTIGEN 1; ERYTHROCYTE BINDING ANTIGEN 175; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; MEROZOITE SURFACE PROTEIN 1; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AGE DISTRIBUTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNICITY; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE TEST; IMMUNOREACTIVITY; INCIDENCE; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MOZAMBICAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGE FACTORS; ANTIBODIES, PROTOZOAN; ANTIBODY FORMATION; ANTIGENS, PROTOZOAN; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; MALARIA, FALCIPARUM; MALE; MEMBRANE PROTEINS; MEROZOITE SURFACE PROTEIN 1; MOZAMBIQUE; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

EID: 84856445146     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05523-11     Document Type: Article

References (55)

1. Alonso PL, et al. 2004. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364:1411-1420. (Pubitemid 39370716)
2. Alonso PL, et al. 2002. Manhiça DSS, Mozambique, p 189-195. In INDEPTH (ed), Population and health in developing countries. Population, health, and survival at INDEPTH sites, 1st ed, vol 1. International Development Research Centre (IDRC), Ottawa, Ontario, Canada.
3. Alonso PL, et al. 1994. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 344:1175-1181. (Pubitemid 24323705)
4. Aucan C, et al. 2000. High immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human resistance to Plasmodium falciparum malaria. Infect. Immun. 68:1252-1258. (Pubitemid 30108518)
5. Cavanagh DR, et al. 2004. Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria. Infect. Immun. 72:6492-6502. (Pubitemid 39425430)
6. Cohen S, McGregor IA, Carrington S. 1961. Gamma-globulin and acquired immunity to human malaria. Nature 192:733-737.
7. Coley AM, et al. 2007. Structure of the malaria antigen AMA1 in complex with a growth-inhibitory antibody. PLoS Pathog. 3:1308-1319. (Pubitemid 47510283)
8. Conway DJ, et al. 2000. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat. Med. 6:689-692. (Pubitemid 30398794)
9. Chitnis CE. 2001. Molecular insights into receptors used by malaria parasites for erythrocyte invasion. Curr. Opin. Hematol. 8:85-91. (Pubitemid 32207556)
10. Deloron P, et al. 1997. Isotypic analysis of maternally transmitted Plasmodium falciparum-specific antibodies in Cameroon, and relationship with risk of P. falciparum infection. Clin. Exp. Immunol. 110:212-218. (Pubitemid 27469593)
11. Dobaño C, et al. 2008. Differential antibody responses to Plasmodium falciparum merozoite proteins in Malawian children with severe malaria. J. Infect. Dis. 197:766-774. (Pubitemid 351364480)
12. Dodoo D, et al. 2008. Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children. Malar. J. 7:142.
13. Doolan DL, Dobaño C, Baird JK. 2009. Acquired immunity to malaria. Clin. Microbiol. Rev. 22:13-36.
14. Duah NO, Miles DJ, Whittle HC, Conway DJ. 2010. Acquisition of antibody isotypes against Plasmodium falciparum blood stage antigens in a birth cohort. Parasite Immunol. 32:125-134.
15. Egan AF, et al. 1996. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J. Infect. Dis. 173:765-769. (Pubitemid 26069671)
16. Eisenhut M. 2007. Immunity to blood stages of Plasmodium falciparum is dependent on a specific pattern of immunoglobulin subclass responses to multiple blood stage antigens. Med. Hypotheses 69:804-808. (Pubitemid 47248132)
17. Fowkes FJ, Richards JS, Simpson JA, Beeson JG. 2010. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-analysis. PLoS Med. 7:e1000218.
18. Garty BZ, Ludomirsky A, Danon YL, Peter JB, Douglas SD. 1994. Placental transfer of immunoglobulin G subclasses. Clin. Diagn. Lab. Immunol. 1:667-669. (Pubitemid 2164290)
19. Gomez-Escobar N, et al. 2010. Erythrocyte invasion and merozoite ligand gene expression in severe and mild Plasmodium falciparum malaria. J. Infect. Dis. 201:444-452.
20. Gray JC, et al. 2007. Profiling the antibody immune response against blood stage malaria vaccine candidates. Clin. Chem. 53:1244-1253. (Pubitemid 47020980)
21. Greenwood B, Marsh K, Snow R. 1991. Why do some African children develop severe malaria? Parasitol. Today 7:277-281. (Pubitemid 121007888)
22. John CC, et al. 2005. Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. Am. J. Trop. Med. Hyg. 73:222-228. (Pubitemid 41278777)
23. Kocken CH, et al. 2002. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infect. Immun. 70:4471-4476. (Pubitemid 34790958)
24. Macete E, et al. 2006. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J. Infect. Dis. 194:276-285. (Pubitemid 44116968)
25. Mazumdar S, Sachdeva S, Chauhan VS, Yazdani SS. 2010. Identification of cultivation condition to produce correctly folded form of a malaria vaccine based on Plasmodium falciparum merozoite surface protein-1 in Escherichia coli. Bioprocess Biosyst. Eng. 33:719-730.
26. McCarra MB, et al. 2011. Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria. Pediatr. Infect. Dis. J. 30:1037-1042.
27. Menendez C, et al. 2008. A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic. PLoS One 3:e1934.
28. Mewono L, et al. 2008. Interleukin-21 is associated with IgG1 and IgG3 antibodies to erythrocyte-binding antigen-175 peptide 4 of Plasmodium falciparum in Gabonese children with acute falciparum malaria. Eur. Cytokine Netw. 19:30-36.
29. Nebie I, et al. 2008. Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Infect. Immun. 76:759-766. (Pubitemid 351251748)
30. Ned RM, et al. 2008. Effect of placental malaria and HIV infection on the antibody responses to Plasmodium falciparum in infants. J. Infect. Dis. 198:1609-1619.
31. O'Donnell RA, et al. 2001. Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J. Exp. Med. 193:1403-1412. (Pubitemid 32565969)
32. Oeuvray C, et al. 1994. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 84:1594-1602. (Pubitemid 24273030)
33. Ogutu BR, et al. 2009. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One 4:e4708.
34. Okenu DM, et al. 2000. Analysis of human antibodies to erythrocyte binding antigen 175 of Plasmodium falciparum. Infect. Immun. 68:5559-5566.
35. Okoko BJ, et al. 2001. The influence of placental malaria infection and maternal hypergammaglobulinemia on transplacental transfer of antibodies and IgG subclasses in a rural West African population. J. Infect. Dis. 184:627-632. (Pubitemid 32783555)
36. Osier FH, et al. 2008. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect. Immun. 76:2240-2248. (Pubitemid 351656161)
37. Pandey KC, et al. 2002. Bacterially expressed and refolded receptor binding domain of Plasmodium falciparum EBA-175 elicits invasion inhibitory antibodies. Mol. Biochem. Parasitol. 123:23-33. (Pubitemid 34880088)
38. Pattnaik P, et al. 2007. Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175. Vaccine 25:806-813. (Pubitemid 44856130)
39. Perraut R, et al. 2005. Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. J. Infect. Dis. 191:264-271.
40. Polley SD, et al. 2004. Human antibodies to recombinant protein constructs of Plasmodium falciparum apical membrane antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 23:718-728. (Pubitemid 39473204)
41. Quelhas D, et al. 2008. Impact of intermittent preventive treatment with sulfadoxine-pyrimethamine on antibody responses to erythrocytic-stage Plasmodium falciparum antigens in infants in Mozambique. Clin. Vaccine Immunol. 15:1282-1291.
42. Richards JS, et al. 2010. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin. Infect. Dis. 51:e50-e60.
43. Riley EM, et al. 2000. Lack of association between maternal antibody and protection of African infants from malaria infection. Infect. Immun. 68:5856-5863.
44. Roussilhon C, et al. 2007. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med. 4:e320.
45. Sabchareon A, et al. 1991. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am. J. Trop. Med. Hyg. 45:297-308.
46. Saute F, et al. 2003. Malaria in southern Mozambique: malariometric indicators and malaria case definition in Manhica district. Trans. R. Soc. Trop. Med. Hyg. 97:661-666. (Pubitemid 41051073)
47. Schellenberg D, et al. 2005. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 365:1481-1483. (Pubitemid 40591693)
48. Schellenberg D, et al. 1999. African children with malaria in an area of intense Plasmodium falciparum transmission: features on admission to the hospital and risk factors for death. Am. J. Trop. Med. Hyg. 61:431-438. (Pubitemid 29428716)
49. Serra-Casas E, et al. 2010. The effect of intermittent preventive treatment during pregnancy on malarial antibodies depends on HIV status and is not associated with poor delivery outcomes. J. Infect. Dis. 201:123-131.
50. Sim BK, et al. 1990. Primary structure of the 175K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion. J. Cell Biol. 111:1877-1884.
51. Simister NE. 2003. Placental transport of immunoglobulin G. Vaccine 21:3365-3369. (Pubitemid 36792087)
52. Snounou G, et al. 1993. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Mol. Biochem. Parasitol. 61:315-320.
53. Stanisic DI, et al. 2009. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect. Immun. 77:1165-1174.
54. Toure FS, Deloron P, Migot-Nabias F. 2006. Analysis of human antibodies to erythrocyte binding antigen 175 peptide 4 of Plasmodium falciparum. Clin. Med. Res. 4:1-6.
55. Wilson S, et al. 2007. Age-adjusted Plasmodium falciparum antibody levels in school-aged children are a stable marker of microgeographical variations in exposure to Plasmodium infection. BMC Infect. Dis. 7:67.